Recon Catalyst OrthoScience Demonstrates Leadership in Procedural Efficiency with Addition of Fracture to Its Single-Tray Portfolio byTim AllenApril 16, 2026
Recon Regulatory Catalyst OrthoScience Announces FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty byJosh SandbergFebruary 25, 2026
Recon Regulatory Catalyst OrthoScience Receives FDA 510(k) Clearance for Expanded Indications of the Fracture Shoulder System byJosh SandbergDecember 3, 2025
Financial Recon Catalyst OrthoScience Secures $15.0 Million in Growth Financing byTim AllenOctober 22, 2025
Recon Top Stories Catalyst OrthoScience Announces Full Commercial Release of Fracture Shoulder System byJosh SandbergAugust 13, 2025
Recon Top Stories Catalyst OrthoScience Announces 5-8 Year Data Reporting Significant Functional Improvement and Pain Reduction for Anatomic Total Shoulder Arthroplasty byTim AllenJune 4, 2025
Recon Catalyst OrthoScience Announces Leadership Transition: Miguel A. Ramirez, MD, Appointed Chief Medical Officer byJosh SandbergApril 2, 2025
Recon Regulatory Top Stories Catalyst OrthoScience Announces FDA 510(k) Clearance for Shoulder Fracture System and First Cases byJosh SandbergOctober 15, 2024
Financial Recon Top Stories Catalyst OrthoScience Surpasses 10,000 Total Shoulder Arthroplasty (TSA) Procedures and Announces $20 Million Financing byJosh SandbergSeptember 10, 2024
Extremities Catalyst OrthoScience Announces Amy Ables, Ph.D. as Chief Strategy Officer byJosh SandbergNovember 20, 2023
